Given the established roles of NFκB in angiogenesis, cell invasion, oncogenesis, proliferation, and inhibition of apoptosis, inhibition of this important transcription factor is widely regarded as an attractive strategy of cancer therapy and a primary mechanism of bortezomib anti-tumor activity in MM cells [4,9,10]. This evidence concerns the gene NFKB1 and Miyoshi myopathy.